loading page

Medication related jaw osteonecrosis (MRONJ) late onset 3 years after IPILIMUMAB endovenous administration: a possible role of target therapy
  • +2
  • Agostino Guida,
  • Francesco Perri,
  • Franco Ionna,
  • Paolo A Ascierto,
  • Antonio Maria Grimaldi
Agostino Guida
INT – IRCCS “Fondazione G. Pascale”, Naples, Italy
Author Profile
Francesco Perri
Istituto Nazionale Tumori IRCCS Fondazione Pascale
Author Profile
Franco Ionna
INT – IRCCS “Fondazione G. Pascale”, Naples, Italy
Author Profile
Paolo A Ascierto
INT – IRCCS “Fondazione G. Pascale”, Naples, Italy
Author Profile
Antonio Maria Grimaldi
INT – IRCCS “Fondazione G. Pascale”, Naples, Italy
Author Profile

Abstract

Ipilimumab has been associated to medication related jaw osteonecrosis (MRONJ) only two times in literature. A woman underwent therapy with ipilimumab for Metastatic Melanoma in 2015 and she developed MRONJ in 2018. She was successfully treated with medical therapy alone. Vigilance in dental management of these patients is needed.

Peer review status:UNDER REVIEW

03 Jun 2020Submitted to Clinical Case Reports
15 Jul 2020Submission Checks Completed
15 Jul 2020Assigned to Editor
19 Jul 2020Reviewer(s) Assigned
27 Jul 2020Review(s) Completed, Editorial Evaluation Pending
08 Sep 20201st Revision Received
10 Sep 2020Submission Checks Completed
10 Sep 2020Assigned to Editor
10 Sep 2020Review(s) Completed, Editorial Evaluation Pending
11 Sep 2020Reviewer(s) Assigned